| Year |
Citation |
Score |
| 2024 |
Liss MA, Zeltser N, Zheng Y, Lopez C, Liu M, Patel Y, Yamaguchi TN, Eng SE, Tian M, Semmes OJ, Lin DW, Brooks JD, Wei JT, Klein EA, Tewari AK, ... ... Kagan J, et al. Upgrading of Grade Group 1 Prostate Cancer at Prostatectomy: Germline Risk Factors in a Prospective Cohort. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 39158404 DOI: 10.1158/1055-9965.EPI-24-0326 |
0.513 |
|
| 2020 |
Kohaar I, Chen Y, Banerjee S, Borbiev T, Kuo HC, Ali A, Kagan J, Srivastava S, Dobi A, Sesterhenn IA, Rosner IL, Cullen J, Srivastava S, Petrovics G. A Urine Exosome Gene Expression Panel Distinguishes Between Indolent and Aggressive Prostate Cancers at Biopsy. The Journal of Urology. 101097JU000000000000. PMID 32945736 DOI: 10.1097/Ju.0000000000001374 |
0.597 |
|
| 2020 |
Wang YT, Shi T, Srivastava S, Kagan J, Liu T, Rodland KD. Proteomic Analysis of Exosomes for Discovery of Protein Biomarkers for Prostate and Bladder Cancer. Cancers. 12. PMID 32825017 DOI: 10.3390/Cancers12092335 |
0.404 |
|
| 2020 |
Gao Y, Wang YT, Chen Y, Wang H, Young D, Shi T, Song Y, Schepmoes AA, Kuo C, Fillmore TL, Qian WJ, Smith RD, Srivastava S, Kagan J, Dobi A, et al. Proteomic Tissue-Based Classifier for Early Prediction of Prostate Cancer Progression. Cancers. 12. PMID 32429558 DOI: 10.3390/Cancers12051268 |
0.43 |
|
| 2020 |
Tan S, Young D, Huang W, Ali A, Ravindranath L, Christen K, Babcock K, Kuo H, Chen Y, Kagan J, Srivastava S, Dobi A, Alagarsamy S, Petrovics G, McLeod DG, et al. Abstract C023: Annexin A2 expression level correlates with adverse pathology and disease progression in prostate cancer Cancer Epidemiology, Biomarkers & Prevention. DOI: 10.1158/1538-7755.Disp18-C023 |
0.49 |
|
| 2020 |
Kohaar I, Banerjee S, Chen Y, Ali A, Kagan J, Srivastava S, Cullen J, Rosner I, Srivastava S, Petrovics G. Abstract A111: Urine-based gene expression panels with focus on prostate cancer in African Americans Cancer Epidemiology, Biomarkers & Prevention. DOI: 10.1158/1538-7755.Disp18-A111 |
0.53 |
|
| 2019 |
Yan W, Jamal M, Tan SH, Song Y, Young D, Chen Y, Katta S, Ying K, Ravindranath L, Woodle T, Kohaar I, Cullen J, Kagan J, Srivastava S, Dobi A, et al. Molecular profiling of radical prostatectomy tissue from patients with no sign of progression identifies as the strongest independent predictor of recurrence. Oncotarget. 10: 6466-6483. PMID 31741711 DOI: 10.18632/Oncotarget.27294 |
0.502 |
|
| 2019 |
Gao Y, Wang Y, Wang H, Young D, Cullen J, Song Y, Chen Y, Schepmoes A, Petrovics G, Fillmore T, Shi T, Qian W, Smith R, Srivastava S, Kagan J, et al. Abstract 3165: Identification of candidate biomarkers for aggressive prostate cancer using targeted proteomics and FFPE tissue samples with outcomes data Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-3165 |
0.504 |
|
| 2019 |
Tan S, Martinez A, Rastogi A, Huang W, Banerjee S, Ravindranath L, Young D, Ali A, Kohaar I, Chen Y, Cullen J, Petrovics G, Dobi A, McLeod DG, Kagan J, et al. Abstract 3296: Tumor antigens Fetuin-A and Secreted Protein Acidic and Rich in Cysteine (SPARC) Autoantibodies as diagnostic and prognostic biomarkers in prostate cancer Cancer Research. 79: 3296-3296. DOI: 10.1158/1538-7445.Am2019-3296 |
0.622 |
|
| 2019 |
Kohaar I, Banerjee S, Chen Y, Ali A, Kagan J, Srivastava S, Cullen J, Rosner I, Srivastava S, Petrovics G. Pd11-09 Development Of Race Specific Urine Based Gene Expression Panels For Prostate Cancer The Journal of Urology. 201. DOI: 10.1097/01.Ju.0000555365.82349.11 |
0.552 |
|
| 2018 |
Srivastava S, Ghosh S, Kagan J, Mazurchuk R. The PreCancer Atlas (PCA). Trends in Cancer. 4: 513-514. PMID 30064657 DOI: 10.1016/J.Trecan.2018.06.003 |
0.341 |
|
| 2018 |
Dobi A, Petrovics G, Li H, Young D, Chen Y, Kagan J, Srivastava S, Ebner R, Rosner IL, Cullen J, Freedman ML, Sesterhenn IA, Szallasi Z, Srivastava S. Abstract PR01: Distinct genomic alterations in prostate cancer of African American men Cancer Epidemiology, Biomarkers & Prevention. 27. DOI: 10.1158/1538-7755.Disp17-Pr01 |
0.578 |
|
| 2018 |
Kohaar I, Banerjee S, Ravindranath L, Chen Y, Ali A, Kagan J, Srivastava S, Dobi A, McLeod D, Rosner IL, Srivastava S, Petrovics G. Abstract B42: Development of a urine exosome-based prostate cancer gene expression panel to address racial differences in prostate cancer Cancer Epidemiology, Biomarkers & Prevention. 27. DOI: 10.1158/1538-7755.Disp17-B42 |
0.579 |
|
| 2018 |
Dobi A, Petrovics G, Li H, Young D, Tan S, Chen Y, Xiao Q, Sun Y, Li H, Li Y, Ji Y, Hou J, Wang W, Kagan J, Zhao G, et al. Abstract A018: Distinct genomic alterations in prostate cancer of African American men Cancer Research. 78. DOI: 10.1158/1538-7445.Prca2017-A018 |
0.556 |
|
| 2018 |
Kohaar I, Banerjee S, Ravindranath L, Chen Y, Ali A, Kagan J, Srivastava S, Dobi A, McLeod D, Rosner I, Srivastava S, Petrovics G. Abstract A013: Prostate cancer gene expression panel to address racial differences of molecular alterations in prostate cancer Cancer Research. 78. DOI: 10.1158/1538-7445.Prca2017-A013 |
0.568 |
|
| 2018 |
Tan S, Rastogi A, Banerjee S, Bagga A, Xavier C, Mohamed A, Young D, Petrovics G, Dobi A, Sesterhenn IA, Kagan J, Srivastava S, David DG, Rosner IL, Srivastava S, et al. Abstract 5765: Immunobiomarkers: Structural and functional characterization of single chain fragment variable (scFv) to ERG from a mouse monoclonal antibody Cancer Research. 78: 5765-5765. DOI: 10.1158/1538-7445.Am2018-5765 |
0.433 |
|
| 2018 |
Dobi A, Petrovics G, Tan S, Li H, Young D, Schafer C, Fox J, Babcock K, Hu H, Sukumar G, Song Y, Ravindranath L, Chen Y, Cheng J, Ebner R, ... ... Kagan J, et al. Abstract 5352: Racial/ethnic differences in prostate cancer genomic alterations Cancer Research. 78: 5352-5352. DOI: 10.1158/1538-7445.Am2018-5352 |
0.518 |
|
| 2017 |
Wang H, Barbieri CE, He J, Gao Y, Shi T, Wu C, Schepmoes AA, Fillmore TL, Chae SS, Huang D, Mosquera JM, Qian WJ, Smith RD, Srivastava S, Kagan J, et al. Quantification of mutant SPOP proteins in prostate cancer using mass spectrometry-based targeted proteomics. Journal of Translational Medicine. 15: 175. PMID 28810879 DOI: 10.1186/S12967-017-1276-7 |
0.439 |
|
| 2017 |
Cullen J, Young D, Chen Y, Degon M, Farrell J, Sedarsky J, Baptiste W, Rosen P, Tolstikov V, Kiebish M, Kagan J, Srivastava S, Kuo HC, Moncur JT, Rosner IL, et al. Predicting Prostate Cancer Progression as a Function of ETS-related Gene Status, Race, and Obesity in a Longitudinal Patient Cohort. European Urology Focus. PMID 28753864 DOI: 10.1016/J.Euf.2017.02.016 |
0.557 |
|
| 2017 |
Sanda MG, Feng Z, Howard DH, Tomlins SA, Sokoll LJ, Chan DW, Regan MM, Groskopf J, Chipman J, Patil DH, Salami SS, Scherr DS, Kagan J, Srivastava S, Thompson IM, et al. Association Between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer. Jama Oncology. PMID 28520829 DOI: 10.1001/jamaoncol.2017.0177 |
0.486 |
|
| 2017 |
Kohaar I, Ravindranath L, Banerjee S, Chen Y, Ali A, Song Y, Kagan J, Srivastava S, Dobi A, McLeod D, Rosner IL, Srivastava S, Petrovics G. Abstract 4649: Development of an ethnicity informed gene expression panel with potential to improve prostate cancer diagnosis Cancer Research. 77: 4649-4649. DOI: 10.1158/1538-7445.Am2017-4649 |
0.526 |
|
| 2017 |
Rastogi A, Martinez A, Ali A, Tan S, Cullen J, Chen Y, Petrovics G, Dobi A, Ravindranath L, Young D, Sesterhenn I, Kagan J, Srivastava S, McLeod D, Rosner I, et al. Abstract 2830: Secreted protein acidic and rich in cysteine antigen and autoantibodies in sera of prostate cancer patients: Potential use in diagnosis /prognosis Cancer Research. 77: 2830-2830. DOI: 10.1158/1538-7445.Am2017-2830 |
0.525 |
|
| 2017 |
Wang H, Gao Y, Schepmoes A, Petrovics G, Cullen J, Fillmore T, Shi T, Qian W, Smith R, Weaver B, Leach R, Thompson I, Srivastava S, Kagan J, Dobi A, et al. Abstract 226: Verification of prostate cancer genomics biomarker candidates at protein level using PRISM-SRM Cancer Research. 77: 226-226. DOI: 10.1158/1538-7445.Am2017-226 |
0.538 |
|
| 2017 |
Kohaar I, Ravindranath L, Banerjee S, Chen Y, Ali A, Kagan J, Srivastava S, Dobi A, McLeod D, Rosner I, Srivastava S, Petrovics G. MP33-12 DEVELOPMENT OF A PROSTATE CANCER GENE EXPRESSION PANEL TO ADDRESS RACIAL DIFFERENCES OF MOLECULAR ALTERATIONS IN PROSTATE CANCER Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.1008 |
0.589 |
|
| 2016 |
Rastogi A, Ali A, Tan SH, Banerjee S, Chen Y, Cullen J, Xavier CP, Mohamed AA, Ravindranath L, Srivastav J, Young D, Sesterhenn IA, Kagan J, Srivastava S, McLeod DG, et al. Autoantibodies against oncogenic ERG protein in prostate cancer: potential use in diagnosis and prognosis in a panel with C-MYC, AMACR and HERV-K Gag. Genes & Cancer. 7: 394-413. PMID 28191285 DOI: 10.18632/genesandcancer.126 |
0.432 |
|
| 2016 |
Lee J, Jamal M, Yan W, young D, Song Y, Chen Y, Katta S, Ravindranath L, Srinivasan A, Cullen J, Kagan J, Srivastava S, Dobi A, Rosner IL, McLeod DG, et al. Abstract A35: Increased expression of PCGEM1 lncRNA in prostate cancer of African American men Cancer Research. 76. DOI: 10.1158/1538-7445.Nonrna15-A35 |
0.585 |
|
| 2016 |
Rastogi A, Ali AM, Banerjee S, Ravindranath L, Petrovics G, Tan S, Cullen J, Chen Y, Young D, Sesterhenn IA, Kagan J, Srivastava S, McLeod DG, Srivastava S, Srinivasan A. Abstract 4958: Immunobiomarkers: novel autoantibody panel comprising oncogenic ERG, C-MYC, AMACR and HERV-K Gag for the detection of prostate cancer Cancer Research. 76: 4958-4958. DOI: 10.1158/1538-7445.Am2016-4958 |
0.57 |
|
| 2016 |
Wang H, Barbieri C, He J, Gao Y, Wu C, Schepmoes A, Fillmore T, Shi T, Chae S, Huang D, Mosquera JM, Qian W, Smith R, Srivastava S, Kagan J, et al. Abstract 3872: Quantification of mutant SPOP proteins in prostate cancer using targeted proteomics Cancer Research. 76: 3872-3872. DOI: 10.1158/1538-7445.Am2016-3872 |
0.514 |
|
| 2016 |
Cullen J, Young D, Chen Y, Degon MS, Baptiste W, Farrell JS, Sedarsky JS, Kuo H, Kagan J, Srivastava S, Rosner IL, Petrovics G, Dobi A, McLeod DG, Srivastava S, et al. Abstract 3448: ERG-negative index tumor status combined with obesity predict prostate cancer progression in Caucasian American prostate cancer patients Cancer Research. 76: 3448-3448. DOI: 10.1158/1538-7445.Am2016-3448 |
0.566 |
|
| 2016 |
Dobi A, Petrovics G, Li H, Tan S, Stümpel T, Young D, Katta S, Li Q, Ying K, Klocke B, Ravindranath L, Kohaar I, Chen Y, Ribli D, Grote K, ... ... Kagan J, et al. Abstract 140: LSAMP gene deletion is associated with rapid disease progression in prostate cancer of African American men Cancer Research. 76: 140-140. DOI: 10.1158/1538-7445.Am2016-140 |
0.559 |
|
| 2016 |
Cullen J, Young D, Chen Y, Degon M, Baptist W, Farrell J, Sedarsky J, Kuo CH, Kagan J, Srivastava S, Rosner I, Petrovics G, Dobi A, McLeod D, Srivastava S, et al. MP90-14 DISTINCT BIOLOGICAL FEATURES OF PROSTATE TUMORS IN THE CONTEXT OF RACE/ETHNICITY AND ERG STATUS Journal of Urology. 195. DOI: 10.1016/J.Juro.2016.02.2558 |
0.514 |
|
| 2016 |
Yan W, Young D, Song Y, Chen Y, Katta S, Ying K, Kagan J, Srivastava S, Dobi A, McLeod D, Sesterhenn I, Srivastava S, Petrovics G. MP02-11 A NANOSTRING PLATFORM BASED ASSAY DEFINES ABSENCE OF ERG FUSION OR ATTENUATED ANDROGEN RECEPTOR FUNCTION INDEX (ARFI) AS EARLY INDICATORS OF BIOCHEMICAL RECURRENCE IN A SUBSET OF LOW GRADE PROSTATE CANCER Journal of Urology. 195. DOI: 10.1016/J.Juro.2016.02.1883 |
0.534 |
|
| 2016 |
Rastogi A, Ali A, Banerjee S, Ravindranath L, Petrovics G, Tan S, Cullen J, Chen Y, Young D, Sesterhenn I, Kagan J, Srivastava S, McLeod D, Srivastava S, Srinivasan A. MP02-05 AUTOANTIBODIES AGAINST ERG, AMACR, C-MYC AND HERV GAG IN THE SERA OF PROSTATE CANCER PATIENTS: POTENTIAL USE IN DIAGNOSIS/PROGNOSIS Journal of Urology. 195. DOI: 10.1016/J.Juro.2016.02.1877 |
0.513 |
|
| 2015 |
Petrovics G, Li H, Stümpel T, Tan SH, Young D, Katta S, Li Q, Ying K, Klocke B, Ravindranath L, Kohaar I, Chen Y, Ribli D, Grote K, Zou H, ... ... Kagan J, et al. A novel genomic alteration of LSAMP associates with aggressive prostate cancer in African American men. Ebiomedicine. 2: 1957-64. PMID 26844274 DOI: 10.1016/J.Ebiom.2015.10.028 |
0.485 |
|
| 2015 |
He J, Schepmoes AA, Shi T, Wu C, Fillmore TL, Gao Y, Smith RD, Qian WJ, Rodland KD, Liu T, Camp DG, Rastogi A, Tan SH, Yan W, Mohamed AA, ... ... Kagan J, et al. Analytical platform evaluation for quantification of ERG in prostate cancer using protein and mRNA detection methods. Journal of Translational Medicine. 13: 54. PMID 25889691 DOI: 10.1186/S12967-015-0418-Z |
0.405 |
|
| 2015 |
Sesterhenn I, Young D, Chen Y, Petrovics G, Cullen J, Kagan J, Srivastava S, Rosner IL, McLeod DG, Dobi A, Srivastava S. Racial/ethnic variation in a common genetic alteration in prostate cancer. Journal of Clinical Oncology. 33: 14-14. DOI: 10.1200/Jco.2015.33.7_Suppl.14 |
0.499 |
|
| 2015 |
Dobi A, Degon M, Farrell J, Baptiste W, Young D, Chen Y, Petrovics G, Cullen J, Kagan J, Srivastava S, Rosner I, McLeod DG, Srivastava S, Sesterhenn I. Abstract 5277: ERG-based stratification of prostate cancer highlights ethnicity associated biological differences Cancer Research. 75: 5277-5277. DOI: 10.1158/1538-7445.Am2015-5277 |
0.558 |
|
| 2015 |
Lee J, Yan W, Young D, Song Y, Chen Y, Katta S, Mohamed A, Ravindranath L, Srinivasan A, Cullen J, Kagan J, Srivastava S, Dobi A, Rosner I, McLeod DG, et al. Abstract 2016: Evaluation of prostate cancer biomarkers and therapeutic targets in FFPE specimens using the NanoString platform Cancer Research. 75: 2016-2016. DOI: 10.1158/1538-7445.Am2015-2016 |
0.592 |
|
| 2015 |
He J, Schepmoes A, Rastogi A, Tan S, Yan W, Huang W, Banerjee S, Shi T, Wu C, Fillmore T, Gao Y, Kagan J, Srivastava S, Smith R, Qian W, et al. Abstract 1818: Analytical platform evaluation for quantification of ERG oncoprotein in prostate cancer using protein and mRNA detection methods Cancer Research. 75: 1818-1818. DOI: 10.1158/1538-7445.Am2015-1818 |
0.522 |
|
| 2015 |
Skates SJ, Anderson KS, Liu T, Kulasingam V, Rabideau D, Wu C, Gillette M, Godwin AK, Urban N, Lokshin A, Marks J, Diamandis E, Zhang Z, Srivastava S, Kagan J, et al. Abstract 1570: Early Detection Research Network (EDRN) validation of circulating ovarian cancer biomarkers Cancer Research. 75: 1570-1570. DOI: 10.1158/1538-7445.Am2015-1570 |
0.364 |
|
| 2015 |
Sanda M, Feng Z, Wei J, Howard D, Rubin M, Groskopf J, Sokoll L, Chan D, Regan M, Patil D, Salami S, Siddiqui J, Scherr D, Kagan J, Srivastava S, et al. Pi-08 Combining Urine Pca3 And Tmprss2: Erg Tests To Refine Prostate Cancer Detection – Validation Study And Health Economic Analysis The Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.2907 |
0.523 |
|
| 2015 |
Yan W, Young D, Song Y, Chen Y, Katta S, Ravindranath L, Lee J, Srinivasan A, Cullen J, Kagan J, Srivastava S, Srivastava S, Dobi A, Rosner I, McLeod DG, et al. MP66-06 OPTIMIZATION OF NANOSTRING PLATFORM FOR EVALUATION OF PROSTATE CANCER BIOMARKERS AND THERAPEUTIC TARGETS IN FFPE SPECIMENS Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.2359 |
0.564 |
|
| 2015 |
Dobi A, Degon M, Farrell J, Baptiste W, Young D, Chen Y, Petrovics G, Cullen J, Kagan J, Srivastava S, Rosner I, McLeod DG, Srivastava S, Sesterhenn I. MP61-16 ETHNIC DIFFERENCES OF ERG ONCOGENIC ALTERATION IN PROSTATE CANCER: CONCLUSIONS FROM 1139 WHOLE MOUNT PROSTATES Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.2197 |
0.531 |
|
| 2014 |
Wei JT, Feng Z, Partin AW, Brown E, Thompson I, Sokoll L, Chan DW, Lotan Y, Kibel AS, Busby JE, Bidair M, Lin DW, Taneja SS, Viterbo R, Joon AY, ... ... Kagan J, et al. Can urinary PCA3 supplement PSA in the early detection of prostate cancer? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 4066-72. PMID 25385735 DOI: 10.1200/Jco.2013.52.8505 |
0.516 |
|
| 2014 |
Farrell J, Young D, Chen Y, Cullen J, Rosner IL, Kagan J, Srivastava S, McLEOD DG, Sesterhenn IA, Srivastava S, Petrovics G. Predominance of ERG-negative high-grade prostate cancers in African American men. Molecular and Clinical Oncology. 2: 982-986. PMID 25279185 DOI: 10.3892/mco.2014.378 |
0.509 |
|
| 2014 |
He J, Sun X, Shi T, Schepmoes AA, Fillmore TL, Petyuk VA, Xie F, Zhao R, Gritsenko MA, Yang F, Kitabayashi N, Chae SS, Rubin MA, Siddiqui J, Wei JT, ... ... Kagan J, et al. Antibody-independent targeted quantification of TMPRSS2-ERG fusion protein products in prostate cancer. Molecular Oncology. 8: 1169-80. PMID 25266362 DOI: 10.1016/J.Molonc.2014.02.004 |
0.457 |
|
| 2014 |
Rastogi A, Tan SH, Mohamed AA, Chen Y, Hu Y, Petrovics G, Sreenath T, Kagan J, Srivastava S, McLeod DG, Sesterhenn IA, Srivastava S, Dobi A, Srinivasan A. Functional antagonism of TMPRSS2-ERG splice variants in prostate cancer. Genes & Cancer. 5: 273-84. PMID 25221645 DOI: 10.18632/GENESANDCANCER.25 |
0.401 |
|
| 2014 |
Shi T, Gao Y, Quek SI, Fillmore TL, Nicora CD, Su D, Zhao R, Kagan J, Srivastava S, Rodland KD, Liu T, Smith RD, Chan DW, Camp DG, Liu AY, et al. A highly sensitive targeted mass spectrometric assay for quantification of AGR2 protein in human urine and serum. Journal of Proteome Research. 13: 875-82. PMID 24251762 DOI: 10.1021/Pr400912C |
0.33 |
|
| 2014 |
Dobi A, Rosen P, Farrell J, Degon M, Young D, Srivastava S, Kagan J, Petrovics G, Cullen J, McLeod DG, Sesterhenn IA, Srivastava S. Abstract C18: ERG-focused evaluations of prostate cancer of African American men and its potential impact on utility in biomarker development and in enhanced personalized medicine Cancer Epidemiology, Biomarkers & Prevention. 23. DOI: 10.1158/1538-7755.Disp13-C18 |
0.605 |
|
| 2014 |
Shi T, He J, Wu C, Fillmore TL, Schepmoes AA, Rubin M, Siddiqui J, Wei J, Chinnaiyan A, Liu A, Smith RD, Kagan J, Srivastava S, Rodland KD, Qian W, et al. Abstract 2483: An antibody-independent, complementary SRM strategy for ultrasensitive and multiplexed quantification of cancer biomarker candidates Cancer Research. 74: 2483-2483. DOI: 10.1158/1538-7445.Am2014-2483 |
0.471 |
|
| 2014 |
Dobi A, Chen Y, Ali A, Young D, Rosen P, Farrell J, Degon M, Srivastava S, Kagan J, Lee J, Cullen J, Petrovics G, McLeod DG, Sesterhenn IA, Srivastava S. Abstract 1859: Potential impact on the biology and biomarker utility of ERG-typing in the context of ethnic differences of prostate cancer Cancer Research. 74: 1859-1859. DOI: 10.1158/1538-7445.Am2014-1859 |
0.578 |
|
| 2014 |
Rastogi A, Tan S, Petrovics G, Chen Y, Sreenath T, Srivastava S, Kagan J, McLeod DG, Srivastava S, Srinivasan A, Dobi A. MP41-05 DELINEATION OF THE BIOLOGICAL LINK BETWEEN THE ERG SPLICE VARIANT, ERG8, AND ITS PROGNOSTIC FEATURES Journal of Urology. 191. DOI: 10.1016/J.Juro.2014.02.1222 |
0.503 |
|
| 2014 |
Farrell J, Young D, Degon M, Srivastava S, Kagan J, Cullen J, Petrovics G, Rosner I, McLeod DG, Sesterhenn IA, Srivastava S. MP41-01 HIGHER GRADE PROSTATE CANCER STRATIFICATION BY ERG ONCOPROTEIN AND SPINK1 EXPRESSION IN CAUCASIAN AMERICAN AND AFRICAN AMERICAN MEN Journal of Urology. 191. DOI: 10.1016/J.Juro.2014.02.1218 |
0.544 |
|
| 2013 |
Ankerst DP, Till C, Boeck A, Goodman P, Tangen CM, Feng Z, Partin AW, Chan DW, Sokoll L, Kagan J, Wei JT, Thompson IM. The impact of prostate volume, number of biopsy cores and American Urological Association symptom score on the sensitivity of cancer detection using the Prostate Cancer Prevention Trial risk calculator. The Journal of Urology. 190: 70-6. PMID 23313212 DOI: 10.1016/J.Juro.2012.12.108 |
0.474 |
|
| 2013 |
Feng Z, Kagan J, Pepe M, Thornquist M, Ann Rinaudo J, Dahlgren J, Krueger K, Zheng Y, Patriotis C, Huang Y, Sorbara L, Thompson I, Srivastava S. The Early Detection Research Network's Specimen reference sets: paving the way for rapid evaluation of potential biomarkers. Clinical Chemistry. 59: 68-74. PMID 23193062 DOI: 10.1373/Clinchem.2012.185140 |
0.347 |
|
| 2013 |
He J, Sun X, Shi T, Schepmoes A, Fillmore T, Petyuk V, Xie F, Gritsenko M, Yang F, Kitabayashi N, Chae SS, Rubin M, Siddiqui J, Wei J, Chinnaiyan A, ... ... Kagan J, et al. Abstract 3207: Application of an antibody-free, highly sensitive PRISM-SRM proteomics approach for monitoring low abundance proteins and protein isoforms in cell lines and tumor tissue. Cancer Research. 73: 3207-3207. DOI: 10.1158/1538-7445.Am2013-3207 |
0.377 |
|
| 2012 |
Wei JT, Sanda MG, Thompson IM, Partin A, Feng Z, Sokoll L, Groskopf J, Brown E, Lotan Y, Kibel A, Lin D, Taneja S, Viterbo R, Busby E, Bidair M, ... Kagan J, et al. Abstract 4451: The NCI Early Detection Research Network (EDRN) urinary PCA3 validation trial Cancer Research. 72: 4451-4451. DOI: 10.1158/1538-7445.Am2012-4451 |
0.541 |
|
| 2012 |
Liu T, Shi T, Hossain M, Schepmoes A, Fillmore T, Sokoll LJ, Chan D, Leach R, Thompson I, Smith RD, Kagan J, Srivastava S, Rodland KD, Camp DG, Qian W. Abstract 1268: Accurate measurement of serum total and free PSA using immunoaffinity depletion coupled to SRM: Correlation with clinical immunoassays Cancer Research. 72: 1268-1268. DOI: 10.1158/1538-7445.Am2012-1268 |
0.394 |
|
| 2010 |
Sokoll LJ, Sanda MG, Feng Z, Kagan J, Mizrahi IA, Broyles DL, Partin AW, Srivastava S, Thompson IM, Wei JT, Zhang Z, Chan DW. A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 19: 1193-200. PMID 20447916 DOI: 10.1158/1055-9965.Epi-10-0007 |
0.528 |
|
| 2009 |
Sokoll LJ, Liu Y, Feng Z, Kagan J, Partin AW, Srivastava S, Thompson IM, Wei JT, Elliott D, Sanda MG, Chan DW. [-2]Propsa For Prostate Cancer Detection: A Prospective, Multicenter, Nci Early Detection Research Network Study The Journal of Urology. 181: 772-772. DOI: 10.1016/S0022-5347(09)62151-0 |
0.506 |
|
| 2008 |
Sokoll LJ, Wang Y, Feng Z, Kagan J, Partin AW, Sanda MG, Thompson IM, Chan DW. [-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study. The Journal of Urology. 180: 539-43; discussion 5. PMID 18550118 DOI: 10.1016/J.Juro.2008.04.015 |
0.506 |
|
| 2008 |
McLerran D, Grizzle WE, Feng Z, Thompson IM, Bigbee WL, Cazares LH, Chan DW, Dahlgren J, Diaz J, Kagan J, Lin DW, Malik G, Oelschlager D, Partin A, Randolph TW, et al. SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer. Clinical Chemistry. 54: 53-60. PMID 18024530 DOI: 10.1373/Clinchem.2007.091496 |
0.333 |
|
| 2008 |
McLerran D, Grizzle WE, Feng Z, Bigbee WL, Banez LL, Cazares LH, Chan DW, Diaz J, Izbicka E, Kagan J, Malehorn DE, Malik G, Oelschlager D, Partin A, Randolph T, et al. Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias. Clinical Chemistry. 54: 44-52. PMID 17981926 DOI: 10.1373/Clinchem.2007.091470 |
0.423 |
|
| 2007 |
Kagan J, Srivastava S, Barker PE, Belinsky SA, Cairns P. Towards Clinical Application of Methylated DNA Sequences as Cancer Biomarkers: A Joint NCI's EDRN and NIST Workshop on Standards, Methods, Assays, Reagents and Tools. Cancer Research. 67: 4545-9. PMID 17510378 DOI: 10.1158/0008-5472.Can-06-2888 |
0.354 |
|
| 2005 |
Vijayakumar S, Garcia D, Hensel CH, Banerjee M, Bracht T, Xiang R, Kagan J, Naylor SL. The human Y chromosome suppresses the tumorigenicity of PC-3, a human prostate cancer cell line, in athymic nude mice. Genes, Chromosomes & Cancer. 44: 365-72. PMID 16080199 DOI: 10.1002/Gcc.20250 |
0.342 |
|
| 2005 |
Semmes OJ, Feng Z, Adam BL, Banez LL, Bigbee WL, Campos D, Cazares LH, Chan DW, Grizzle WE, Izbicka E, Kagan J, Malik G, McLerran D, Moul JW, Partin A, et al. Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. Clinical Chemistry. 51: 102-12. PMID 15613711 DOI: 10.1373/Clinchem.2004.038950 |
0.468 |
|
| 2004 |
Grizzle WE, Semmes OJ, Basler J, Izbicka E, Feng Z, Kagan J, Adam BL, Troyer D, Srivastava S, Thornquist M, Zhang Z, Thompson IM. The early detection research network surface-enhanced laser desorption and ionization prostate cancer detection study: A study in biomarker validation in genitourinary oncology. Urologic Oncology. 22: 337-43. PMID 15283893 DOI: 10.1016/J.Urolonc.2004.04.008 |
0.513 |
|
| 2004 |
Parnes HL, House MG, Kagan J, Kausal DJ, Lieberman R. Prostate cancer chemoprevention agent development: the National Cancer Institute, Division of Cancer Prevention portfolio. The Journal of Urology. 171: S68-74; discussion S. PMID 14713758 DOI: 10.1097/01.ju.0000107220.64675.74 |
0.439 |
|
| 2003 |
Grizzle WE, Adam BL, Bigbee WL, Conrads TP, Carroll C, Feng Z, Izbicka E, Jendoubi M, Johnsey D, Kagan J, Leach RJ, McCarthy DB, Semmes OJ, Srivastava S, Srivastava S, et al. Serum protein expression profiling for cancer detection: validation of a SELDI-based approach for prostate cancer. Disease Markers. 19: 185-95. PMID 15258333 DOI: 10.1155/2004/546293 |
0.343 |
|
| 2001 |
Yin Z, Babaian RJ, Troncoso P, Strom SS, Spitz MR, Caudell JJ, Stein JD, Kagan J. Limiting the location of putative human prostate cancer tumor suppressor genes on chromosome 18q. Oncogene. 20: 2273-80. PMID 11402322 DOI: 10.1038/Sj.Onc.1204310 |
0.647 |
|
| 2000 |
Liu J, Babaian DC, Liebert M, Steck PA, Kagan J. Inactivation of MMAC1 in bladder transitional-cell carcinoma cell lines and specimens. Molecular Carcinogenesis. 29: 143-50. PMID 11108659 DOI: 10.1002/1098-2744(200011)29:3<143::Aid-Mc3>3.0.Co;2-A |
0.328 |
|
| 2000 |
Spitz MR, Strom SS, Yamamura Y, Troncoso P, Babaian RJ, Scardino PT, Wheeler T, Amos CI, von Eschenbach A, Kagan J. Epidemiologic determinants of clinically relevant prostate cancer. International Journal of Cancer. Journal International Du Cancer. 89: 259-64. PMID 10861502 DOI: 10.1002/1097-0215(20000520)89:3<259::Aid-Ijc8>3.0.Co;2-F |
0.526 |
|
| 1999 |
Yin Z, Spitz MR, Babaian RJ, Strom SS, Troncoso P, Kagan J. Limiting the location of a putative human prostate cancer tumor suppressor gene at chromosome 13q14.3. Oncogene. 18: 7576-83. PMID 10602517 DOI: 10.1038/sj.onc.1203203 |
0.411 |
|
| 1998 |
Kagan J, Liu J, Stein JD, Wagner SS, Babkowski R, Grossman BH, Katz RL. Cluster of allele losses within a 2.5 cM region of chromosome 10 in high-grade invasive bladder cancer. Oncogene. 16: 909-13. PMID 9484782 DOI: 10.1038/Sj.Onc.1201606 |
0.393 |
|
| 1997 |
el-Naggar AK, Hurr K, Kagan J, Gillenwater A, Callender D, Luna MA, Batsakis JG. Genotypic alterations in benign and malignant salivary gland tumors: histogenetic and clinical implications. The American Journal of Surgical Pathology. 21: 691-7. PMID 9199647 DOI: 10.1097/00000478-199706000-00009 |
0.318 |
|
| Show low-probability matches. |